Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].

Anales del sistema sanitario de Navarra - 24 Jun 2026

Gámiz Rejano Arturo, Gago Sánchez Ana Isabel, Rodríguez Alonso Rosa María

Abstract excerpt

Intrahepatic cholangiocarcinoma is a poor prognosis malignancy with limited therapeutic options in advanced stages. Identification of actionable molecular alterations may enable targeted therapies in selected patients. We describe a 74-year-old man with metastatic intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation, treated off-label in the second-line setting with dabrafenib (150 mg twice daily) plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Imidazoles

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 42340756
DOI: 10.23938/ASSN.1159
PMCID: PMC13386458

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].PMID 42340756Read ↗

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

BRAF V600E-mutant intrahepatic cholangiocarcinoma treated successfully with encorafenib, binimetinib, and cetuximabSemantic proximity Read ↗

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.Semantic proximity Read ↗

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.Semantic proximity Read ↗

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports.Semantic proximity Read ↗

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.Semantic proximity Read ↗

Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.Semantic proximity Read ↗

Exploring the Clinical Use of Molecular Profiling of Intrahepatic Cholangiocarcinoma in a Comprehensive Multidisciplinary Clinic.Semantic proximity Read ↗

The evolving role of futibatinib for advanced cholangiocarcinoma.Semantic proximity Read ↗

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.Semantic proximity Read ↗

Complete Response for Adding Pyrotinib to Pembrolizumab and Lenvatinib for HER2 Positive Advanced Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.